Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 6 weeks of age (range: 42-48 days).~* Parents that consent for participation in the full length of the study.~* Parents that are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* Evidence of a chronic medical condition identified during physical exam.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of IPV or collection of blood by venipuncture.~* Acute diarrhea, infection or illness at the time of enrollment (6 weeks of age) that would require infant's admission to a hospital or would contraindicate provision of OPV or IPV per country guidelines.~* Acute vomiting and intolerance to liquids within 24 hours before the enrollment visit (6 weeks of age).~* Receipt of any polio vaccine (OPV or IPV) before enrollment based upon documentation or parental recall.~* Known allergy/sensitivity or reaction to polio vaccine or contents of polio vaccine.~* Infants from multiple births. Infants from multiple births will be excluded to reduce the potential for contact transmission of vaccine poliovirus to siblings. The infant(s) from a multiple birth who is/are not enrolled would be likely to receive routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Infants from premature births (\<37 weeks of gestation).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 7 Weeks
- Healthy Volunteers: t

Study Arms:
- mOPV2 at 6 and 7 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
- mOPV2 at 6 and 8 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
- mOPV2 at 6 and 10 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
- mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age (Type: ACTIVE_COMPARATOR): Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age

Based on this trial design, predict the completion outcome and termination type (if applicable).